Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointments of key members of its leadership team, including Timothy Kieffer, Ph.D., as Chief Scientific Officer; Danny Villeneuve as Chief Commercial Officer;

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during May: Bank of America Global Healthcare Conference 2025 in Las VegasPresentation: Thursday, May 15 at 12:35 p.m. ET H.C. Wainwright 3rd Annual BioConnect Investor Conference in New YorkPresentation: Tuesday, May 20 at 3:30 p.m. ET 2025 RBC Capital Markets Global Healthcare Conference in New YorkPresentation: Wednesday, May 21 at 2:35 p.m. ET Live

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. DEXA scans analysis from the PWS Phase 2 trial data measuring body composition indicated a trend toward decreased body fat (approximately 1.5%) and increased lean muscle (over 2%) following 28 days of ARD-101 dosing.Ongoing ARD-101 Phase 3 HERO trial to treat hyperphagia associated with PWS is expected to generate topline data in early

10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

10-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

SCHEDULE 13G - Aardvark Therapeutics, Inc. (0001774857) (Subject)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

Morgan Stanley initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $29.00

BofA Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $22.00

RBC Capital Mkts initiated coverage of Aardvark Therapeutics with a rating of Outperform and set a new price target of $21.00

Cantor Fitzgerald initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $50.00

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)